Generate reproducible tissue biomarker data with integrated histopathology, digital pathology, and spatial biology solutions that support faster, more informed clinical development decisions.
Delivering high-quality histopathology data requires more than laboratory testing alone. It demands experienced pathologists, harmonized workflows, validated analytical approaches, and scientific teams who understand how tissue biomarkers align with study objectives, clinical endpoints, and regulatory expectations.
We combine histopathology expertise, immunohistochemistry (IHC), digital pathology, spatial biology, and advanced image analysis within a globally connected laboratory network built to support biomarker strategies across oncology, inflammation and immunology, neurology, metabolic disease, infectious disease, and rare disease programs.
From assay development and tissue qualification through to centralized pathology review and quantitative image analysis, we generate reproducible, clinically relevant tissue insights that help you reduce uncertainty, accelerate development, and move promising therapies closer to patients.
Our teams support your tissue biomarker strategy across every phase of clinical development, with integrated histopathology, molecular analysis, and digital workflows to deliver consistent, decision-ready data.
Immunohistochemistry is a foundational tool for tissue biomarker characterization, supporting patient stratification, disease profiling, pharmacodynamic assessment, and translational research.
We work with you to develop, validate, and transfer tissue biomarker assays that align with your study objectives – from exploratory research through late-phase clinical trials. Whether supporting primary or secondary endpoints, standardized workflows and pathology-guided interpretation help ensure reproducible and clinically meaningful results across sites.
Our experience spans established and emerging biomarkers, including PD-L1, HER2, and ER/PR, supporting consistent application across oncology and other therapeutic areas.
Capabilities include:
Digital pathology enables consistent tissue assessment across geographically distributed clinical programs, helping to standardize interpretation and scale analysis across sites.
We combine pathology expertise with advanced imaging and analysis workflows to support centralized review, reduce variability, and deliver quantitative tissue data aligned with your study endpoints. This integrated approach helps ensure that complex tissue data is interpreted consistently and translated into decision-ready insights.
By aligning imaging, analysis, and pathology interpretation, we help you generate reproducible results that meet both scientific and regulatory expectations.
Capabilities include:
Spatial biology approaches help characterize biomarker expression within the tissue microenvironment, providing additional context beyond single-marker analysis alone.
We support multiplex and spatial workflows that combine tissue morphology with protein and transcriptomic data, enabling a more complete view of tissue biology. This added context is critical when exploring mechanisms of action, resistance, and complex disease pathways that extend beyond single-marker analysis.
By integrating spatial and molecular data, you can generate deeper insight into tissue architecture while maintaining alignment with your study objectives.
Capabilities include:
Access to high-quality tissue samples is critical for biomarker development and translational research. Pathologist-reviewed sourcing and standardized sample management processes help ensure that samples are fit for purpose and aligned with your study requirements.
We support both retrospective and prospective studies with access to well-characterized tissue collections across multiple disease areas. Through rigorous qualification and quality control, we help you reduce variability at the sample level and generate more reliable downstream data.
This ensures that the tissue data generated across your program is both robust and clinically relevant.
Capabilities include:
Generate high-quality tissue data through integrated histopathology expertise, combining morphology, biomarker analysis, and pathology-led interpretation across clinical development.
Enable standardized and quantitative tissue assessment with digital pathology workflows, whole-slide imaging, and AI-assisted image analysis for reproducible results.
Support biomarker characterization with robust immunohistochemistry solutions, including assay development, optimization, and validated antibody-based analysis.
Explore complex tissue biology using multiplex immunofluorescence and in situ hybridization techniques that enable multi-biomarker detection within tissue context.
Characterize tissue biology with spatial transcriptomics and proteomics solutions that combine morphology with molecular insight.
Learn how AI-assisted image analysis improves reproducibility and quantitative accuracy of Ki-67 scoring in solid tumor tissue samples.
Understand how multiplex IHC assay validation supports robust, reproducible quantification of regulatory T-cell biomarkers in clinical trial tissue studies.
Explore how multiplex immunofluorescence enables detailed immune checkpoint profiling and deeper characterization of complex tumor immune microenvironments.
Discover how spatially resolved multiplex analysis reveals regulatory and effector T-cell interactions within the tumor microenvironment across multiple tissue types.
Learn how biomarkers support patient stratification, endpoint selection, and more informed decision-making across clinical development programs.
